

Index

- Acetic acid, 44
“Acid-hematoxylin” staining, 44
Adenoacanthoma, 159, 160
Adenocarcinoma, 159, 178, 245.
 See also Carcinoma;
 Endometrial intraepithelial
 neoplasm
 diagnosis, 219
“Adenomatous change,” 195–196, 202
Adenomatous epithelial aggregates,
 235, 236, 242
Adenosquamous carcinoma, 159,
 161–163
Anisopoikilonucleosis, 222, 224, 225
Antibodies, 251, 254, 255
Apoptosis, 52, 56
Arias-Stella reaction, 62, 63, 178
Atrophic endometrium, glands of, 78,
 79, 81
Atrophy, endometrial, 76, 84, 93.
 See also “Swiss cheese”
 endometrium
 cancer and, 190
 cell nuclei and, 78, 80, 81, 84,
 85, 90
 cysts and, 76, 84–87, 89
 epithelium and, 76, 77, 80, 85–93
 histiocytes and, 84, 88, 89
 hormones and, 93–94
 overview, 76
 proliferation and, 77
 stroma and, 76, 81–84
Atypia, 233. *See also* Carcinoma,
 nuclear grades and
 cytoarchitectural patterns;
 Nuclear atypia
Benign endometrial abnormalities,
 29–30, 32, 33, 37, 97, 98.
 See also specific conditions
Benign hyperplasia. *See* Hyperplasia,
 benign
Beta-catenin, 156
Biopsy, 5–8, 25
Bleeding, 5–6, 30, 32, 110, 111, 124
 protracted, chronic, 115, 116
Brushing(s), endometrial, 2. *See also*
 Tau brush
 hysterectomy outcomes, 26, 27, 37, 38
Carcinoma, endometrial, 20, 36, 178,
 262. *See also* Endometrial
 intraepithelial cancer;
 Endometrial intraepithelial
 neoplasm; *specific topics*
 background, 231–233
 heritable, 232
 nuclear grades and
 cytoarchitectural patterns,
 233–234, 242, 250. *See*
 also Nuclear grade
 secretory, 244, 248, 249

- Carcinoma, endometrial, (*Continued*)
 tamoxifen and, 168, 170, 178
 type 1, 235, 244, 249
 epithelial bridges without
 stromal support and,
 210, 217
 mucinous metaplasia and,
 210, 211
 overview, 231–232,
 234–235
 tubuloacinar structures and,
 213, 214, 216
 type 2, 231, 232, 249–251,
 256. *See also* Clear
 cell carcinoma; Serous
 carcinoma
- Carcinosarcoma, 244, 256,
 261–266
 types of, 262, 263
- CD10 immunostaining, 159, 268
- Ciliated metaplasia, 159,
 164–166, 178
- Clear cell carcinoma, 226, 251,
 254–259
 immunoreactivity for ER and PR
 proteins, 251
 putative precursor lesions
 for, 226
 serous carcinoma and, 251
- Clear cell metaplasia, 165, 170, 178
- Clustered nuclear pseudostratification,
 205, 206
- Colorectal cancer, hereditary
 nonpolyposis, 232–233
- Confocal microscopy, 15
- Cribiforming and cribriform structures,
 235–238
- Cysts, 76, 84–87, 89
- Cytological sampling, 5–8
- Cytoplasmic dominance. *See*
 Nuclear vs. cytoplasmic
 dominance
- Deciduoid cells, 57, 59, 60, 65
- Dyshesive epithelial aggregates, 244,
 246, 247
- Endometria, histologically normal,
 27–29
- Endometrial cytology, 5–7. *See also*
specific topics
 performance characteristics in
 hysterectomy-controlled
 environment, 25–27, 31,
 32, 37–38
 benign endometrial
 abnormalities, 29–30, 33, 37
 histologically normal
 endometria, 27–29
 neoplasms, 33, 34–36
- Endometrial grand dysplasia (EmGD),
 35, 221–226, 251
- Endometrial intraepithelial cancer
 (EIC), 35, 37, 115, 221–225
 serous, 221, 251. *See also* Serous
 carcinoma
- Endometrial intraepithelial cancer/
 endometrial grand dysplasia
 (EIC/EmGD), 222–226, 251
- Endometrial intraepithelial neoplasm
 (EIN), 33–35, 231
 benign hyperplasia and, 117–119
 conceptual basis, 191–194
 cytological, 195–202
 with features of endometroid
 neoplasia, 204–205, 210,
 219–221
 brush cytology preparations, 205
 histological, 194–195
 therapeutic consequences,
 202–204
- Endometrial intraepithelial neoplasm
 (EIN) lesions, 165
- Endometrial sampling, office-based,
 5–8
- Endometritis, 120–131, 137, 138
 forms, 124, 136
 acute, 120
 granulomatous, 127–128,
 132–134
 nodular histiocytic, 124,
 129–131
 nodular lymphoid, 135, 136
 ichthyosis uteri and, 154, 155

- Endometrium
 hypermature, 30, 31
 comprising disordered
 proliferation and
 nonatypical hyperplasia,
 97–120
 inflammation, 137. *See also*
 Inflammatory cells
 lymphoma of, 128, 136
 menstrual, 64, 67, 68–75
 neoplastic, 189–190
 normal, 39, 40
 secretory, 46, 48, 52, 56–57,
 62, 64
 deciduoid cells and, 57, 59,
 60, 65
 stromal sarcoma of, 267–274
 Endometroid neoplasia, 204–205,
 210, 219–221. *See also*
 Secretory adenocarcinoma
 cytoarchitectural features, 220
 Endomyometrial necrosis,
 postablation, 146–150
 Eosinophilic cell change, 165–168
 Eosinophils, 127
 Epithelial aggregates, 235, 236,
 242–244, 246, 247
 Epithelial bridges, 218
 without stromal support, 210,
 211, 217
 Epithelial cribriform structures,
 235–238
 Epithelial cysts, 76, 84–87, 89
 Epithelial metaplasias. *See* Metaplasia
 Epithelial nuclei, 15, 16. *See also*
 Nuclei
 Epithelial tufts, 205, 207–210
 Epithelium, 92
 with atypical (cancer-like) nuclei,
 191, 196
 Estrogen, 104, 120, 178. *See also*
 Carcinoma, type 1;
 Tamoxifen
 EIN and, 191–194
 foam cells and, 180–182
 type 2 carcinoma and, 251
 Fibrin thrombi, 104, 108, 109
 Fibrous stroma, 142–144
 FIGO histological grading system. *See*
 Carcinoma
 Fixative, primary, 279–280
 Foam cells, 180–185
 Genetics and cancer, 232–233, 261
 Gestagens, 178
 Glands, 79
 involution and fracturing of, 70
 Glandular cells, 48, 49
 Glycogen, 209
 Grades of cancer. *See* Carcinoma
 Granulomatous endometritis, IUD-
 associated, 127–128,
 132–134
 Hematoxylin, 44
 Hereditary nonpolyposis colorectal
 cancer (HNPCC), 232–233
 Histiocytes
 endometrial atrophy and, 84, 88, 89
 foam cells and, 89, 180–182
 Histiocytic endometritis, nodular, 124,
 129–131
 HLA-DR-positive cells, 62
 Hobnail cell metaplasia, 178, 179
 Hormonal therapy, 203. *See also*
 Tamoxifen
 Hormone replacement therapy, 93–94
 Hyperplasia, 20, 30, 31, 86, 139, 204
 atypical. *See also* Endometrial
 intraepithelial neoplasm
 reproducibility of diagnosis
 of, 219
 benign, 214
 cytology of, 105
 complex, 117
 distinguishing between grade 1
 adenocarcinoma and, 219, 220
 fractal dimension, 195
 nonatypical, 97–99, 102–107, 110,
 117–120
 Hysterectomy, 220. *See also under*
 Brushing(s)

- Ichthyosis uteri, 154–156
 Immunology, 254, 255. *See also* CD10 immunostaining; Natural killer (NK) cells
 Immunoreactivity
 for ER and PR proteins, 251
 of stromal cells, 62
 Infections, 124
 Inflammation, 138
 Inflammatory cells, 120–122
 Intrauterine device (IUD)-associated
 granulomatous
 endometritis, 127–128,
 132–134

 Keratinizing squamous metaplasia. *See*
 Squamous metaplasia and
 morules

 Luminal fibrin thrombosis, 104, 108.
 See also Fibrin thrombi
 Lymphoid endometritis, nodular,
 135, 136
 Lymphoma, MALT, 128, 136
 Lynch syndrome, 232–233

 Menstrual endometrium. *See*
 Endometrium, menstrual
 Metaplasia, 93. *See also* Squamous
 metaplasia and morules;
 specific metaplasias
 in neoplasia, 178, 180
 overview, 153–154
 Metaplastic epithelial clumps,
 112–114
 “Microcancer,” 202–203
 Morules. *See also* Squamous
 metaplasia and morules
 histological characteristics, 156, 157
 Mucinous metaplasia, 165, 167, 168, 170
 type 1 carcinoma and, 210, 211
 types of, 168, 169–173, 175, 176, 211
 Myometrial necrosis (myonecrosis).
 See Endomyometrial
 necrosis

 Natural killer (NK) cells, 56, 57
 Necrosis. *See* Endomyometrial
 necrosis
 Neoplasia
 endometrioid, 204–205. *See also*
 Secretory adenocarcinoma
 metaplasia in, 178, 180
 Neoplasms, endometrial, 33, 34–36,
 146. *See also* Carcinoma;
 Endometrial intraepithelial
 cancer; Endometrial
 intraepithelial neoplasm;
 specific topics
 cytology of high-grade
 malignancy, 262
 Neoplastic endometrium, 189–190
 Neutrophilic emperipolesis, 210, 212
 Nodular histiocytic endometritis, 124,
 129–131
 Nodular lymphoid endometritis, 135, 136
 Nuclear anaplasia, 110
 Nuclear atypia, 91, 253
 as basis for cytology risk-
 stratification of endometrial
 samplings, 15, 17–21, 23
 EIC/EmGD and, 222–226
 Nuclear crowding and pseudo-
 stratification, 205, 206
 Nuclear grade. *See also under*
 Carcinoma
 diagnosis and, 28, 35, 36
 and risk of endometrial
 abnormality, 22, 23, 28, 34
 Nuclear vs. cytoplasmic dominance, 48
 Nuclei, cell, 15, 16–19. *See also under*
 Epithelium
 endometrial atrophy and, 78, 80,
 81, 84, 85, 90

 Outpatient sampling, 5–8

 Papillary structures, 212, 241
 Papillary syncytial metaplasia,
 112–114
 “Picket-fencing,” 205, 206
 “Pill effect,” 65, 66

- Pipelle biopsy, 5, 7–8, 11
- Plasma cells, 120, 123, 124, 128
- Polyethylene glycol (PEG), 280–281, 286
- Polymer encapsulation solution, 280–281
- Polymorphonuclear leukocytes (PMNs)
- endometritis and, 120, 121–123, 125
 - insinuation into budding and papillary syncytial epithelial structures of surface endometrium, 212
 - intraglandular accumulation of, 120, 121–123, 125
 - menstruation and, 68
 - myometrial necrosis and, 146–148
- Polyps, 30, 32, 33, 136, 139–142
- brush collections, 142, 143
 - malignant and premalignant, 146
 - in postmenopausal women, 146
 - stroma, 142–145
 - thick-walled blood vessels, 142, 143
- Precancer, endometrial, 146, 178.
- See also* Endometrial intraepithelial neoplasm; *specific conditions*
 - background, 189–191, 226–227
- Pregnancy-related cells, 57, 60, 61
- Progesterone, 119–120, 251
- Progestins, 119–120, 203, 220, 249
- Proliferative endometrium, 39–47
- benign, 30
- Pseudostratification, clustered nuclear, 205, 206
- PTEN protein, 193, 203
- Pyometra, 136–138
- Rhabdoid cells, 263, 264
- Sarcoma, 244, 265. *See also* Carcinosarcoma; Stromal sarcoma of endometrium
- Secretory adenocarcinoma, 244, 248, 249
- types of, 249
- Secretory endometrium. *See* Endometrium, secretory
- Secretory hyperplasia, 120
- Serous carcinoma, 221, 249–256
- clear cell carcinoma and, 251
- Slide-coating reagent, 281–282
- Specimen processing, 282–290
- Squamous metaplasia and morules, 154–163
- Stroma/stromal cells, 57–59, 62, 126
- atrophic, 76, 81–84
 - deciduoid, 57, 59, 66. *See also* Deciduoid cells
 - epithelial sheets and, 71
 - fibrous, 142–144
 - heterogeneity, 62
 - immunoreactivity, 62
 - menstrual, 64, 66, 67, 71, 72, 75
 - of ovulatory or interval period, 48
 - of polyps, 141, 142
 - proliferative phase, 46, 47
 - subepithelial and periglandular, 141, 142, 144, 145
- Stromal breakdown, focal, 124
- Stromal sarcoma of endometrium, 267–274
- Stromal support, epithelial bridges
- without, 210, 211, 217
- Suction biopsy, 5
- “Swiss cheese” endometrium, 86, 87, 104, 201
- Syncytial change, epithelial tufts
- of, 205, 207, 208
- Syncytial metaplasia. *See* Papillary syncytial metaplasia
- Tamoxifen, 168, 170, 178
- Tau brush, 1, 7–8, 11–13, 25, 124
- Tubal metaplasia, 159, 164–166
- Tubuloacinar gland irregularity and compression of tubuloacinar structures, 210, 213–216
- Tufted epithelial structures, 205, 207–210
- Tumerogenesis, endometrial
- dualistic model of, 231
- Tumor nuclei, 15, 17–22
- Villoglandular structures, 235, 236, 239–241
- VLA-1, 62